

curve: a model for the safe reintegration of elective interventional pain procedures. *Pain Phys.* 2020;23:S449-S451.

9. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet.* 2021;397:220-32.

10. Kaur A, Singh L, Singh N, et al. Ameliorative effect of imipramine in chemically induced fibromyalgia: Role of NMDA/NFkB mediated downstream signaling. *Biochem Pharmacol.* 2019;166:56-69.

11. Kemp HL, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. *Brit J Anaesth.* 2020;125(4):436-40.

12. Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? *Front Med.* 2021;7:606824.

13. Lacasse A, Pagé MG, Dassieu L, et al. Impact of the COVID-19 pandemic on the pharmacological, physical, and

psychological treatment of pain: findings from the Chronic pain & COVID-19 Pan-Canadian Study. *Pain Rep.* 2021\_6\_e891.

14. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):16144.

15. Meo SA, Bukhari IA, Akram J, et al. COVID-19 Vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. *Eur Rev Med Pharmacol Sci.* 2021;25:1663-69.

16. Meyer-Friessem CH, Giertmühlen J, Baron R, et al. Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge. *Pain Rep.* 2021;6:e893.

17. Mun CJ, Campbell CM, McGill LS, Aaron RV. The early impact of COVID-19 on chronic pain: A cross-sectional investigation of a large online sample of individuals with chronic pain in the United States, April to May, 2020. *Pain Med.* 2021;22(2):470-80.

18. Murphy MT, Latif U. Pain during COVID-19: A comprehensive review and guide for the interventionalist. *Pain Pract.* 2021;21(1):132-43.

19. Rýdlová J, Fabiánová J. Myalgická encefalomyelitida – praktická aplikace Mezinárodních konsenzuálních kritérií. *Med praxi.* 2013;10(4):160-62.

20. Salaffi F, Giorgi V, Sirotti S, et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. *Clin Exp Rheumatol.* 2020. PMID: 33200740.

21. Serrano-Ibanez ER, Esteve R, Ramirez-Maestre C, et al. Chronic pain in the time of COVID-19: Stress aftermath and central sensitization. *Brit J Health Psychol.* 2020; doi: 10.1111/bjhp.12483.

22. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. *Front Immunol.* 2021. doi: 10.3389/fimmu.2021.714170.

## ON-LINE KURZ

# On-line kurz pro praktické neurology 2022

## Trendy v léčbě migrény

### PŘEDNÁŠKY

- Význam studie PEARL pro klinickou praxi – MUDr. Jolana Marková, FEAN
- Medication overuse headache a role anti-CGRP – MUDr. Petra Migalová
- Lékové interakce migréna a RS – update – PharmDr. Josef Suchopár
- Výhody flexibility podání fremanezumabu u našich pacientů – MUDr. Monika Záhumenská

### ODBORNÝ GARANT

MUDr. Jolana Marková, FEAN  
Neurologická klinika, Fakultní Thomayerova nemocnice v Praze

POČET  
KREDITŮ **2**

Registrace  
ZDARMA

### TERMÍN

prosinec 2022  
až listopad 2023  
dostupný na  
[online.solen.cz](http://online.solen.cz)

PARTNER

teva

